Mugglehead
Subscribe

Medtronic gains FDA clearance for Hugo robot in general surgery

The expanded indication covers procedures performed about 3.5 million times annually in the U.S., extending Hugo beyond urology.

Adrian Kessler·
A mixed-media collage shows generic robotic surgical equipment with cool blue brush strokes.
A collage of generic robotic surgical equipment. Illustration: Mugglehead, generated with AI.

U.S. hospitals can expand Hugo robotic surgery beyond urology after Medtronic plc NYSEMDT announced FDA clearance for general surgery on Tuesday. Medtronic estimates the newly covered procedures account for about 3.5 million operations annually in the United States, expanding the system's commercial opportunity.

The Nov. 17 release describes an expanded 510(k) clearance covering all upper-abdominal general surgical procedures, including gallbladder removal, Roux-en-Y gastric bypass, ventral hernia repair and small bowel resection. The lower-abdominal procedures covered are inguinal hernia repair and appendectomy.

Medtronic is a large medical technology company headquartered in Galway, Ireland, supplying surgical instruments, cardiovascular devices and patient-monitoring systems worldwide.

Shares closed at US$102.86 in New York at 4:00 p.m. EST on Nov. 13 NYSEMDT, before the clearance announcement. Medtronic's next financial report is scheduled for Nov. 24.

Hugo Is Already In U.S. Clinical Use

Medtronic says Hugo is in clinical use at a growing number of U.S. hospitals and health systems. Its Nov. 17 release gives no hospital count or dated rollout schedule for the expanded general surgery uses.

The company's current indications and safety information limits the system to adult use by trained physicians in an operating room. The labelling also includes abdominal wall hernia procedures alongside upper-abdominal general surgery and the specified lower-abdominal procedures.

The labelling says the evaluation assessed Hugo as a surgical tool for controlling instruments. It did not assess cancer-treatment outcomes or treatment of a particular underlying disease. Potential adverse events include bleeding, infection, burns and bowel or vessel perforation.

Read more: Tandem Diabetes Care wins FDA clearance for tubeless Mobi set worn up to seven days

Hugo uses separate robotic arm carts that teams can position for a procedure and the patient's anatomy, while its open console keeps the surgeon connected with the operating-room team. Medtronic says surgeons can also use its LigaSure RAS Maryland vessel-sealing instrument with the system.

"Hugo expands choice with a practical option to help hospitals address capacity and access challenges, while giving surgical teams more flexibility to meet patients' needs across care settings," Medtronic's Surgical business president Matt Anderson said in the release.

Medtronic expects worldwide Hugo procedures to surpass 50,000 by its fiscal year-end, according to the Nov. 17 announcement. That global forecast differs from the estimated annual U.S. procedure opportunity, which includes operations regardless of the technology used.

Intuitive Reports 14 Per Cent Procedure Growth

Intuitive Surgical, Inc. NASDAQISRG reported on Oct. 20 that its installed base reached 12,094 da Vinci systems at Sept. 30. Worldwide da Vinci procedures increased approximately 14 per cent in the third quarter from a year earlier.

Intuitive's instruments and accessories revenue rose 18 per cent to US$1.80 billion in the third quarter of 2026. Its release attributed the increase primarily to procedure growth across da Vinci and Ion, illustrating the recurring instrument sales associated with greater system use.

The iShares U.S. Medical Devices ETF NYSEARCAIHI traded at US$58.02 at 8:00 p.m. EST on Nov. 13. That sector price also predates the Hugo announcement.

The clearance concerns Medtronic's existing surgical platform, separately from its Nov. 16 proposed acquisition of privately held Contego Medical, Inc. Medtronic valued that vascular-device transaction at US$380 million, with potential payments after acquisition and closing subject to customary conditions.

Read more: Medtronic plans US$380M Contego Medical acquisition for vascular portfolio

Medtronic will report fiscal second-quarter results on Nov. 24, covering the period ended Oct. 30. The report will show operating performance before the expanded general surgery clearance.

More in Health & Science

View all